title: Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia.
abstract: Lifibrol (4-(4'-tert-butylphenyl)-1-(4'carboxyphenoxy)-2-butanol), a new hypocholesterolemic drug, effectively reduces total cholesterol (CH), low density lipoprotein (LDL)-CH, and apolipoprotein (apo) B in experimental animals and in humans. The impact of Lifibrol on the metabolism of apoB-100 containing lipoproteins in patients with hyperlipoproteinemia using endogenous labeling with stable isotopes is examined. Kinetic studies were performed in four male hypercholesterolemic individuals (type IIa) before and on treatment with 450 mg of Lifibrol daily for 4 weeks, and in five male individuals suffering from mixed hyperlipidemia (type IIb) before and on therapy for 12 weeks. Kinetic parameters were estimated by multicompartmental modeling. Lifibrol therapy reduced total CH by 16% (P = 0.012) in all patients, increased triglycerides (TG) by 11% (not significant) in type IIa patients and decreased TG by 34% (P = 0.059) in type IIb patients. During Lifibrol therapy, LDL apoB-100 concentrations decreased by 19% (P = 0.011) in all patients. The decrease in LDL apoB concentrations with Lifibrol therapy was due to an overall increase (75%, P = 0.006) of the fractional catabolic rates (FCR) of LDL apoB. This increase was partially attenuated by a 33% increase in LDL apoB production rate (PR) (P = 0.041). The overall production of apoB increased only slightly. Our data suggest that the major mechanism by which Lifibrol lowers LDL-CH is an increase in receptor-mediated catabolism of LDL rather than a decrease in hepatic apoB production.
authors.affiliation: Department of Medicine, University of Freiburg, Germany. kwinkler@ukl.uni-freiburg.de
authors.forename: K
authors.initials: K
authors.lastname: Winkler
authors.forename: J R
authors.initials: JR
authors.lastname: Schäfer
authors.forename: B
authors.initials: B
authors.lastname: Klima
authors.forename: C
authors.initials: C
authors.lastname: Nuber
authors.forename: A
authors.initials: A
authors.lastname: Sattler
authors.forename: I
authors.initials: I
authors.lastname: Friedrich
authors.forename: W
authors.initials: W
authors.lastname: Köster
authors.forename: A
authors.initials: A
authors.lastname: Steinmetz
authors.forename: H
authors.initials: H
authors.lastname: Wieland
authors.forename: W
authors.initials: W
authors.lastname: März
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001055:Apolipoproteins B / Q000187:drug effects* / Q000378:metabolism; D000440:Butanols / Q000008:administration & dosage*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D062385:Hydroxybenzoates / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D006949:Hyperlipidemias / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D000440:Butanols; D062385:Hydroxybenzoates; D008077:Lipoproteins, LDL; C059343:lifibrol